Aim: To investigate the predictive value of platelet to lymphocyte and neutrophil to lymphocyte ratios for hepatocellular carcinoma outcomes
Material and Methods: 37 hepatocellular carcinoma patients were retrospectively collected. All of the hepatocellular carcinoma patients were treated with conventional methods; transarterial chemoembolization, radiofrequency ablation or both. The patient and tumor characteristics, platelet to lymphocyte ratio and neutrophil to lymphocyte ratio were recorded. The association between platelet to lymphocyte ratio and neutrophil to lymphocyte ratio and tumor free survival rates, recurence rates, need of repeated conventional therapy were analyzed.
Results: The mean MELD (model for end stage liver disease) score of 37 hepatocellular carcinoma patients was 10.75±4.484 (mean age 59.59±17.23 years). High platelet to lymphocyte ratio and neutrophil to lymphocyte ratio were found to be associated with hepatocellular carcinoma recurrence (p0.05). Platelet to lymphocyte ratio and neutrophil to lymphocyte ratios were significantly high in patients who had repated transarterial chemoembolisation, radiofrequency ablation or both (p
Key words: Hepatocellular Carcinoma; Platelet To Lymphocyte Ratio; Neutrophil To Lymphocyte Ratio; Treatment Response; Recurrence.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
